Toggle Main Menu Toggle Search

Open Access padlockePrints

The Newcastle University research output collection, currently available on ePrints, will shortly be moving to a new open repository platform, Figshare. To prepare for the data migration we have paused adding new content to ePrints, and will resume once the new repository is launched. During this time you will continue to have access to ePrints (but no new content will appear). We will share updates here when available.

Analysis of peripheral blood T-cell subsets in active thyroid-associated ophthalmopathy: Absence of effect of octreotide-LAR on T-cell subsets in patients with thyroid-associated ophthalmopathy

Lookup NU author(s): Dr Bijayeswar Vaidya, Dr Brian Shenton, Susan Stamp, Dr Alison Dickinson, Dr Petros PerrosORCiD, Professor Pat Kendall-Taylor

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Thyroid-associated Ophthalmopathy (TAO) is thought to be a T-cell-mediated autoimmune disorder. We sought to characterize abnormalities in the peripheral blood T-cell subsets in patients with TAO, and examine whether the long-acting somatostatin analogue, octreotide-LAR, treatment affects these cells. We analyzed peripheral blood T-cell subsets by flow cytometry in 26 euthyroid patients with moderately severe active TAO and 24 controls. Twenty-five of the patients with TAO were enrolled in a randomized trial to receive either 30 mg of octreotide-LAR (n = 11) or placebo (n = 14) every 4 weeks for 16 weeks; all 25 patients subsequently received octreotide-LAR 30 mg every 4 weeks from week 16 to 32. T-cell subsets were analysed at baseline, week 16, and week 32. At baseline, the relative percentage of CD4+ helper T-cells (p = 0.0003) and the CD4+/CD8+ ratio (p = 0.008) were significantly higher in patients with TAO compared to controls. Patients with TAO had higher naïve active T cells (CD45RA+, CD45RA+CD4 +) and lower memory T cells (CD45RO+, CD45RO +CD4+) than controls. At weeks 16 and 32, there were no significant differences in any T-cell subsets between the octreotide-LAR-treated and placebo groups. These results support a role of T cell in the pathogenesis of TAO, and show that octreotide-LAR has no effect on T-cell subsets during 32-weeks of treatment. © Mary Ann Liebert, Inc.

Publication metadata

Author(s): Vaidya B, Shenton BK, Stamp S, Miller M, Baister E, Andrews CD, Dickinson AJ, Perros P, Kendall-Taylor P

Publication type: Article

Publication status: Published

Journal: Thyroid

Year: 2005

Volume: 15

Issue: 9

Pages: 1073-1078

Print publication date: 01/09/2005

ISSN (print): 1050-7256

ISSN (electronic): 1557-9077

Publisher: Mary Ann Liebert, Inc.

URL: http://dx.doi.org/10.1089/thy.2005.15.1073

DOI: 10.1089/thy.2005.15.1073

PubMed id: 16187917

Altmetrics

Altmetrics provided by Altmetric

Share